BioCentury | Mar 20, 2020
Translation in Brief

Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar

Gates Foundation grants Vaxxas $5M for low-dose vaccine patch   Vaxxas Pty. Ltd. received a $5 million grant Tuesday from the Bill and Melinda Gates Foundation to develop its high-density microarray patch (HD-MAP) to deliver...
BC Week In Review | Oct 3, 2016
Clinical News

Afluria Quadrivalent: Phase III data

CSL’s Seqirus unit reported data from a double-blind, U.S. Phase III trial in 2,278 children ages 5-17 showing that intramuscular Afluria Quadrivalent met the primary endpoint of non-inferior immunogenicity to Fluarix Quadrivalent as assessed by...
BC Week In Review | Oct 3, 2016
Clinical News

Afluria Quadrivalent: Phase III data

CSL’s Seqirus unit reported data from a double-blind, U.S. Phase III trial in 3,484 adults ages >=18 showing that intramuscular Afluria Quadrivalent met the primary endpoint of non-inferiority to Afluria trivalent influenza vaccine and a...
BC Week In Review | Sep 5, 2016
Clinical News

Afluria Quadrivalent regulatory update

FDA approved an sBLA from CSL’s Seqirus unit for Afluria Quadrivalent to prevent infection from 2 influenza subtypes A and 2 influenza type B viruses contained in the vaccine in people ages >=18. Seqirus said...
Items per page:
1 - 4 of 4